AGC Biologics S.p.A.
http://www.agcbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AGC Biologics S.p.A.
Finance Watch: Venture Rounds Trend Toward The High End
Private Company Edition: First quarter data again confirm fewer but larger VC rounds in Q1. Big Q2 rounds include a $132.5m series C round for Endeavor Biomedicines, a $103m series A round for Reunion Neuroscience and Enlaza’s $100m series A.
LENZ Sees Big Commercial Market After Presbyopia Trial Success
LENZ announced successful results from its Phase III pivotal trial of LNZ100 and plans to apply for US FDA approval in the middle of this year, with commercialization in Q2 2025.
AstraZeneca, Ionis Win A Key US FDA Approval With Wainua For ATTR Polyneuropathy
AstraZeneca adds an important product to its cardiovascular, renal and metabolism (CVRM) portfolio and Ionis gains the first drug it will commercialize as it prepares for its first wholly owned launch.
Finance Watch: $1.3bn In New Venture, Equity Capital Across Three New Funds
Private Company Edition: Revelation Partners amassed $608m, Bioluminescence Ventures emerged with $477m and Abingworth raised $356m for late-stage programs. In recent financings, MapLight closed a $225m series C round while Triveni launched with $92m and Gate garnered $60m in series A rounds.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- AGC Biologics
- Molecular Medicine SpA
- MolMed S.p.A.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice